quinazolines has been researched along with Hepatitis B in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsuliman, T; Bazarbachi, A; Beauvais, D; Bonnin, A; Brissot, E; Mear, JB; Souchet, L; Villate, A; Yakoub-Agha, I | 1 |
| Cheng, S; Du, C; Fan, X; Fu, J; Gao, Y; Li, N; Ma, J; Markowitz, GJ; Qin, W; Wang, H; Yang, B; Yang, P | 1 |
1 review(s) available for quinazolines and Hepatitis B
| Article | Year |
|---|---|
[Antiviral prophylaxis for CMV, HSV/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Topics: Acetates; Adult; Allografts; Antiviral Agents; Cytomegalovirus Infections; Hematopoietic Stem Cell Transplantation; Hepatitis B; Herpes Simplex; Herpes Zoster; Humans; Quinazolines; Transplantation Conditioning | 2020 |
1 other study(ies) available for quinazolines and Hepatitis B
| Article | Year |
|---|---|
CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemokine CCL22; Drug Resistance, Neoplasm; Hep G2 Cells; Hepatitis B; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, CCR4; Signal Transduction; Sorafenib; T-Lymphocytes; Tumor Burden | 2020 |